In a clinical trial setting, canagliflozin treatment in individuals with diabetic kidney disease decreased the levels of inflammation and fibrosis biomarkers, including IL-6, matrix metallopeptidase 7 (MMP7) and fibronectin 1(FN1) [112]. This evidence concerns the gene FN1 and diabetic kidney disease.